With youth suicides on the rise, the American Academy of Pediatrics and American Foundation for Suicide Prevention, in collaboration with experts from the National Institute of Mental Health (NIMH), created a document to support pediatric health clinicians.
While antidepressants and psychotherapy have helped many women with postpartum depression (PPD), established pharmacologic approaches for MDD do not target the proposed mechanisms of PPD, and studies have shown that a substantial number of patients with PPD do not achieve remission with antidepressants. We interviewed 3 experts on the subject.
Rheumatologists Leanna M. Wise, MD, and Rajat Bhatt, MD, and researcher Matthew A. Turk, MSc, discuss the effects of alcohol consumption in patients with rheumatoid arthritis and evaluate existing literature on the inverse association between alcohol intake and RA.
To explore the different dimensions of acne in the pediatric population, we spoke with clinical dermatologists who are actively involved in the management of acne in children, adolescents, and young adults.
The author comments on the current situation where behavioral modification smartphone apps do not undergo any oversight such as safety or efficacy studies, nor do they go through the Institutional Review Board to guide or evaluate ethics.
Jiu-Chiuan Chen, MD, ScD and Diana Younan, PhD, MPH discuss the importance of understanding the relationship between air pollution and dementia risk and how clinicians can help patients mitigate their risk.
Two experts speak about how apps address different needs and use different technologies, but taken together, they shed light on the manifold ways that apps can be used for depression management in clinical practice.
Electroconvulsive therapy was initially utilized as a treatment for schizophrenia. However, it has become more commonly used in treatment-resistant depression since the introduction of antipsychotics to treat schizophrenia. However, for patients with schizophrenia who are not responsive to these medications, ECT remains an essential treatment modality more than 80 years after it was first tested in a human patient.